Glossary
Addiction: A chronic, relapsing disease, characterized by compulsive drug seeking and drug use and by neurochemical and molecular changes in the brain.
Attention deficit hyperactivity
disorder: A disorder that often presents in
early childhood, characterized by inattention,
hyperactivity, and impulsivity.
Central nervous system (CNS): The brain and spinal cord.
Craving: A powerful, often uncontrollable desire for drugs.
Dopamine: A neurotransmitter present in regions of the brain that regulate movement, emotion, motivation, and feelings of pleasure.
Narcolepsy: A disorder characterized by uncontrollable attacks of deep sleep.
Psychomotor stimulants (psychostimulants):
Drugs that increase or enhance the
activity of monoamines (such as dopamine
and norepinephrine) in the brain.
Psychostimulants increase arousal and
activity, as well as heart rate, blood pressure,
and respiration.
Psychosis: A mental disorder characterized
by symptoms such as delusions or
hallucinations and disordered thinking.
Rush: A surge of euphoric pleasure that rapidly follows administration of a drug.
Tolerance: A condition in which higher
doses of a drug are required to produce the
same effect as experienced initially.
Toxic: Damage to an organ or group of
organs.
Withdrawal: A variety of symptoms that
occur after chronic abuse of an addictive
drug is reduced or stopped.
References
Chang L, Ernst T, Speck O, Grob CS. Additive effects of
HIV and chronic methamphetamine use on brain
metabolite abnormalities. Am J Psychiatry
162:361-369, 2005.
Gavrilin MA, Mathes LE, Podell M. Methamphetamine
enhances cell-associated feline immunodeficiency virus
replication in astrocytes. J Neurovirol 8:240-249,
2002.
Huber A, Ling W, Shoptaw S, Gulati V, Brethen P, Rawson
R. Integrating treatments for methamphetamine
abuse: A psychosocial perspective. J Addict Dis
16(4):41-50, 1997.
Johnston LD, O'Malley PM, Bachman JG. Monitoring the
Future: National Results on Adolescent Drug Use,
Overview and Key Findings, 2005. NIH Pub. No. 05-5506, Bethesda, MD: NIDA, NIH, DHHS, 2005.
London ED, Simon SL, Berman SM, Mandelkern MA,
Lichtman AM, Bramen J, Shinn AK, Miotto K, Learn J,
Dong Y, Matochik JA, Kurian V, Newton T, Woods R,
Rawson R, Ling W. Mood disturbances and regional
cerebral metabolic abnormalities in recently abstinent
methamphetamine abusers. Arch Gen Psychiatry
61:73-84, 2004.
National Institute on Drug Abuse. Epidemiologic Trends
in Drug Abuse: Advance Report, Community
Epidemiology Work Group, January 2006. NIH Pub.
No. 06-5878, Bethesda, MD: NIH, DHHS, 2006.
National Institute on Drug Abuse. Epidemiologic Trends in
Drug Abuse: Vol. I., Proceedings of the Community
Epidemiology Work Group, Highlights and Executive
Summary, January 2006. NIH Pub. No. 06-5879,
Bethesda, MD: NIH, DHHS, 2006.
National Institute on Drug Abuse. Epidemiologic Trends in
Drug Abuse: Vol. II., Proceedings of the Community
Epidemiology Work Group, January 2006. NIH Pub.
No. 06-5880, Bethesda, MD: NIH, DHHS, 2006.
Petry NM, Peirce JM, Stitzer ML, Blaine J, Roll JM, Cohen
A. Obert J, Killeen T, Saladin ME, Cowell M, Kirby KC,
Sterling R, Royer-Malvestuto C, Hamilton J, Booth RE,
Macdonald M, Liebert M, Rader L, Burns R, DiMaria J,
Copersino M, Stabile PQ, Kolodner K, Li R. Effect of
prize-based incentives on outcomes in stimulant
abusers in outpatient psychosocial treatment
programs: a national drug abuse treatment clinical
trials network study. Arch Gen Psychiatry
62(10):1148-1156, 2005.
Rawson RA, Marinelli-Casey P, Anglin MD, Dickow A,
Frazier Y, Gallagher C, Galloway GP, Herrell J, Huber
A, McCann MJ, Obert J, Pennell S, Reiber C,
Vandersloot D, Zweben J. A multi-site comparison
of psychosocial approaches for the treatment of
methamphetamine dependence. Addiction
99:708-717, 2003.
Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ,
Gonzalez R, Wolfson T, Grant I. Methamphetamine
dependence increases risk of neuropsychological
impairment in HIV infected persons. J Int
Neuropsychol Soc 10:1-14, 2004.
Substance Abuse and Mental Health Services
Administration (SAMHSA). Results from the 2005
National Survey on Drug Use and Health. NSDUH
Series H-30. DHHS Pub No. SMA 06-4194, Rockville,
MD: DHHS, 2006.
SAMHSA. Office of Applied Studies. Drug Abuse Warning
Network, 2004: National Estimates of Drug-Related
Emergency Department Visits. DAWN Series D-28,
DHHS Pub No. 06-4143, Rockville, MD: DHHS,
2006.
SAMHSA, Office of Applied Studies. Treatment Episode
Data Set (TEDS). Highlights - 2004. National
Admissions to Substance Abuse Treatment Services,
DASIS Series: S-31, DHHS Publication No. (SMA) 06-4140, Rockville, MD: DHHS, 2006.
Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong
MS, Sui Y, Lee JY, Toga AW, Ling W, London ED.
Structural abnormalities in the brains of human
subjects who use methamphetamine. J Neurosci
24:6028-6036, 2004.
Volkow ND, et al. Association of dopamine transporter
reduction with psychomotor impairment in
methamphetamine abusers. Am J Psychiatry
158(3):377-382, 2001.
Volkow ND, et al. Loss of dopamine transporters in
methamphetamine abusers recovers with protracted
abstinence. J Neurosci 21(23):9414-9418, 2001.
Wang G-J, et al. Partial recovery of brain metabolism
in methamphetamine abusers after protracted
abstinence. Am J Psychiatry 161(2):242-248,
2004.
Wouldes T, LaGasse L, Sheridan J, Lester B. Maternal
methamphetamine use during pregnancy and child
outcome: what do we know? N Z Med J 117:U1180,
2004.
|